Primers, kits and applications of microRNA markers for nonalcoholic fatty liver disease
By detecting the content of specific MicroRNA markers miR-1224-5p, miR-2113, miR-202-5p and miR-920 in plasma, combined with the digital PCR platform, the non-invasive and accurate NASH staging diagnosis in the prior art was solved. The non-invasive and quantitatively accurate diagnostic effect is achieved.
Patent Information
- Application Number
- CN202411290063.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-14
AI Technical Summary
The existing technology lacks non-invasive and accurate staging diagnosis of non-alcoholic steatohepatitis (NASH). There is a risk in tissue biopsy and the conventional liver biochemical indicators are not specific. Imaging examinations make it difficult to distinguish between fatty liver and NASH, and it is impossible to accurately evaluate fiber. degree of transformation.
By detecting the content of specific MicroRNA markers miR-1224-5p, miR-2113, miR-202-5p and miR-920 in plasma, using reverse transcription primers and detection primers, combined with digital PCR platform, to provide non-alcoholic fatty Diagnostic kit for hepatitis, calculate P1 and P2 values to assist in NASH staging diagnosis.
A non-invasive, quantitatively accurate, sensitive and specific NASH stage diagnosis is achieved, which can distinguish fatty liver from NASH, accurately evaluate the degree of fibrosis, and replace or assist liver tissue biopsy.
Smart Images

Figure CN118792400B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical testing technology, in particular to primers, a kit and applications of MicroRNA markers for non-alcoholic fatty hepatitis. Background Art
[0002] Nonalcoholic Steatohepatitis (NASH) is a more severe form of nonalcoholic fatty liver disease (NAFLD). The pathogenesis of NASH is complex, characterized by inflammation and damage of liver cells on the basis of fatty liver, which may lead to the development of liver fibrosis, cirrhosis and even liver cancer. There are five levels of NASH staging (F0~4), among which, early NASH is without liver fibrosis or only mild fibrosis (F0~1); fibrotic NASH is combined with significant liver fibrosis or septal fibrosis (F2~3); and NASH cirrhosis is combined with cirrhosis (F4).
[0003] At present, histopathological biopsy is the only gold standard for the clinical staging diagnosis of NASH. However, tissue biopsy is an invasive examination with certain risks and complications, and may be affected by the limitations of sample collection. Other indicators, such as conventional liver biochemical indicators such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), although these markers will increase when the liver is damaged, they are not specific to NASH and cannot accurately reflect the severity or staging of NASH. For example, imaging examinations, including ultrasound, CT or MRI, although they can show the presence of fatty liver, it is difficult to distinguish between fatty liver and NASH, and it is impossible to accurately assess the degree of fibrosis. Therefore, there is an urgent need for a non-invasive method to completely replace or assist the use of liver tissue biopsy in the staging diagnosis of NASH. Summary of the invention
[0004] In order to solve the defects in the prior art, the present invention provides a primer, a kit and an application of a MicroRNA marker for non-alcoholic fatty liver disease, which assists in the staging diagnosis of non-alcoholic fatty liver disease by detecting the content of specific MicroRNA markers (miR-1224-5p, miR-2113, miR-202-5p and miR-920) in plasma, and has the characteristics of being non-invasive, accurate in quantification, and having good sensitivity and specificity.
[0005] To achieve the above object, the present invention adopts the following technical solutions:
[0006] In a first aspect, the present invention provides a use of a MicroRNA marker for non-alcoholic fatty hepatitis in the preparation of a reagent or a detection tool for detecting non-alcoholic fatty hepatitis, wherein the marker is miR-1224-5p, miR-2113, miR-202-5p and miR-920.
[0007] In a second aspect, the present invention provides a reverse transcription primer for detecting a MicroRNA marker, wherein the marker is miR-1224-5p, miR-2113, miR-202-5p and miR-920;
[0008] The reverse transcription primers are:
[0009] The reverse transcription primer sequence (5′-3′) of miR-1224-5p is shown in SEQ ID NO. 1, and the sequence is GTCGTATCCAGTGCCACACGTCCTCGAGGCTTAAGCACTGGATACGACCCACCTCC;
[0010] The reverse transcription primer sequence (5′-3′) of miR-2113 is shown in SEQ ID NO. 2, and the sequence is GTCGTATCCAGTGCCACACGTCCTCGAGGCTTAAGCACTGGATACGACGTGACAGA;
[0011] The reverse transcription primer sequence (5′-3′) of miR-202-5p is shown in SEQ ID NO. 3, and the sequence is GTCGTATCCAGTGCAGTGTCAGAGGTAGTCGCACTGGATACGACCAAAGAAG;
[0012] The reverse transcription primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.4, and the sequence is GTCGTATCCAGTGCGAGCCGTTGAGACCGCAAGTGCACTGGATACGACTACTGCTT.
[0013] In a third aspect, the present invention provides a detection primer for detecting a MicroRNA marker; the markers are miR-1224-5p, miR-2113, miR-202-5p and miR-920; the detection primers are:
[0014] The forward primer sequence (5′-3′) of miR-1224-5p is shown in SEQ ID NO. 5, and the sequence is CGCCGTGAGGACTCGGG;
[0015] The reverse primer sequence (5′-3′) of miR-1224-5p is shown in SEQ ID NO. 6, and the sequence is GTATCCAGTGCCACACGTCCTC;
[0016] The forward primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.7, and the sequence is CGAGCGATTTGTGCTTGGCTC;
[0017] The reverse primer sequence (5′-3′) of miR-2113 is shown in SEQ ID NO. 8, and the sequence is GTATCCAGTGCCACACGTCCTC;
[0018] The forward primer sequence (5 '-3 ') of miR-202-5p is shown in SEQ ID NO.9, and the sequence is CGGCTTCCTATGCATATACT;
[0019] The reverse primer sequence (5′-3′) of miR-202-5p is shown in SEQ ID NO. 10, and the sequence is CAGTGCAGTGTCAGAGGTAGTCG;
[0020] The forward primer sequence (5′-3′) of miR-920 is shown in SEQ ID NO. 11, and the sequence is ACCGCGGGGAGCTGTGGA;
[0021] The reverse primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.12, and the sequence is ATCCAGTGCGAGCCGTTG.
[0022] In a fourth aspect, the present invention provides the use of primers for detecting the MicroRNA marker in the preparation of a reagent or a detection tool for detecting non-alcoholic fatty hepatitis.
[0023] In a fifth aspect, the present invention provides the use of the reverse transcription primer and the detection primer of the MicroRNA marker in the preparation of a reagent or a detection tool for detecting non-alcoholic fatty hepatitis.
[0024] In a sixth aspect, the present invention provides a diagnostic kit for non-alcoholic fatty hepatitis, wherein the kit is used to detect the content of MicroRNA markers in plasma, wherein the markers are miR-1224-5p, miR-2113, miR-202-5p and miR-920.
[0025] Preferably, the kit includes a reverse transcription primer for the MicroRNA marker;
[0026] The reverse transcription primers are:
[0027] The reverse transcription primer sequence (5 '-3 ') of miR-1224-5p is shown in SEQ ID NO.1;
[0028] The reverse transcription primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.2;
[0029] The reverse transcription primer sequence (5 '-3 ') of miR-202-5p is shown in SEQ ID NO.3;
[0030] The reverse transcription primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.4.
[0031] Preferably, the kit includes detection primers for the MicroRNA marker;
[0032] The detection primers are:
[0033] The forward primer sequence (5'-3') of miR-1224-5p is shown in SEQ ID NO.5;
[0034] The reverse primer sequence (5 '-3 ') of miR-1224-5p is shown in SEQ ID NO.6;
[0035] The forward primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.7;
[0036] The reverse primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.8;
[0037] The forward primer sequence (5'-3') of miR-202-5p is shown in SEQ ID NO.9;
[0038] The reverse primer sequence (5'-3') of miR-202-5p is shown in SEQ ID NO.10;
[0039] The forward primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.11;
[0040] The reverse primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.12.
[0041] Preferably, the kit is a kit based on a digital PCR platform.
[0042] Preferably, the process of the kit for detecting the content of MicroRNA markers in plasma is:
[0043] (1) Collect plasma and extract total free RNA;
[0044] (2) using the obtained total free RNA and the reverse transcription primer to configure a reverse transcription reaction system, and performing a reverse transcription reaction to obtain a miRNA reverse transcription sample;
[0045] (3) Using the obtained miRNA reverse transcription sample and the detection primers to configure a miRNA digital PCR detection reaction system, prepare digital PCR reaction droplets, and perform a digital PCR reaction.
[0046] Preferably, the kit detects the content of the MicroRNA marker in plasma and determines the degree of non-alcoholic fatty liver disease in the subject by P1 value and P2 value;
[0047] The calculation formula of the P1 value is as follows:
[0048] P1=e s1 / (1+e s1 );
[0049] Among them, S1=4.147-0.012×m1-0.034×m2+0.013×m3+0.042×m4;
[0050] m1 is the content of miR-1224-5p in the sample; m2 is the content of miR-2113 in the sample; m3 is the content of miR-202-5p in the sample; m4 is the content of miR-920 in the sample;
[0051] P1<0.36 indicates that the subject has no liver fibrosis or only mild fibrosis (F0-1), which is early NASH. When P1>0.36, it indicates that the subject has significant liver fibrosis or septal fibrosis (F2-3), which is fibrotic NASH, or has liver cirrhosis (F4), which is NASH cirrhosis.
[0052] For patients who were classified as fibrotic NASH with significant liver fibrosis or septal fibrosis (F2-3), or NASH cirrhosis with cirrhosis (F4), the P2 value was calculated as follows:
[0053] P2=e s2 / (1+e s2 );
[0054] Among them, S2=2.582+0.002×m1-0.054×m2+0.007×m3+0.026×m4;
[0055] m1 is the content of miR-1224-5p in the sample; m2 is the content of miR-2113 in the sample; m3 is the content of miR-202-5p in the sample; m4 is the content of miR-920 in the sample;
[0056] When P2<0.58, it means that the subject has no liver fibrosis or only mild fibrosis (F0~1), which is early NASH; when P2>0.58, it means that the subject has significant liver fibrosis or septal fibrosis (F2~3), which is fibrotic NASH, or has cirrhosis (F4), which is NASH cirrhosis.
[0057] The beneficial effects of the present invention are:
[0058] The present invention adopts the MicroRNA markers of miR-1224-5p, miR-2113, miR-202-5p and miR-920 to perform staging diagnosis of non-alcoholic fatty liver disease, which is non-invasive, easy to detect and quantitatively accurate, thereby improving the sensitivity and specificity of non-alcoholic fatty liver disease diagnosis.
[0059] The present invention utilizes reverse transcription primers and detection primers of the MicroRNA markers miR-1224-5p, miR-2113, miR-202-5p and miR-920 to detect the content of the MicroRNA markers, and adopts a formula to evaluate the staging grade of the subject's non-alcoholic fatty liver disease, so as to clearly distinguish fatty liver from NASH and accurately evaluate the degree of fibrosis.
[0060] The kit of the present invention is a kit based on a digital PCR platform, and can timely, accurately and specifically assist in the diagnosis of non-alcoholic fatty liver disease staging. BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure 1 ROC curves for the diagnosis of NASH patients in stages F0-1 and F2-4 using markers;
[0062] Figure 2 This is the ROC curve for the diagnosis of NASH patients in stages F2~3 and F4 using markers. DETAILED DESCRIPTION
[0063] In order to enable those skilled in the art to better understand the technical solution of the invention, the present invention is further described in detail below in conjunction with specific implementation methods.
[0064] Example 1
[0065] This embodiment provides a diagnostic kit for non-alcoholic fatty hepatitis, the kit is used to detect the content of MicroRNA markers in plasma; the markers are miR-1224-5p, miR-2113, miR-202-5p and miR-920; the kit includes reverse transcription primers and detection primers of MicroRNA markers;
[0066] The reverse transcription primers are:
[0067] The reverse transcription primer sequence (5 '-3 ') of miR-1224-5p is shown in SEQ ID NO.1;
[0068] The reverse transcription primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.2;
[0069] The reverse transcription primer sequence (5 '-3 ') of miR-202-5p is shown in SEQ ID NO.3;
[0070] The reverse transcription primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.4;
[0071] The detection primers are:
[0072] The forward primer sequence (5'-3') of miR-1224-5p is shown in SEQ ID NO.5;
[0073] The reverse primer sequence (5 '-3 ') of miR-1224-5p is shown in SEQ ID NO.6;
[0074] The forward primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.7;
[0075] The reverse primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.8;
[0076] The forward primer sequence (5'-3') of miR-202-5p is shown in SEQ ID NO.9;
[0077] The reverse primer sequence (5'-3') of miR-202-5p is shown in SEQ ID NO.10;
[0078] The forward primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.11;
[0079] The reverse primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.12.
[0080] Example 2
[0081] (1) Collect plasma and extract total free RNA
[0082] About 3 ml of venous blood was collected and centrifuged at 4°C 2000g for 10 min to separate the upper plasma part. Then, the blood was centrifuged at 4°C 12000g for another 20 min to collect the upper plasma sample. About 200ul of plasma sample was taken and total free RNA was extracted using QIAGEN's miRNeasySerum / Plasma Kit. Note that 10ul of quality control product should be added before extraction. After extraction, the concentration was measured and the concentration of the extracted total free RNA was adjusted to 20~40ng / ul.
[0083] (2) Using the obtained total free RNA and reverse transcription primers to configure a reverse transcription reaction system, a reverse transcription reaction is performed to obtain a miRNA reverse transcription sample.
[0084] The miRNA reverse transcription reaction system is shown in Table 1 (a separate tube is configured for each detection of miR-1224-5p, miR-2113, miR-202-5p, and miR-920).
[0085] Table 1. Reverse transcription reaction system of miRNA and quality control products
[0086]
[0087] In Table 1, the four miRNA reverse transcription primers are:
[0088] The reverse transcription primer sequence (5 '-3 ') of miR-1224-5p is shown in SEQ ID NO.1;
[0089] The reverse transcription primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.2;
[0090] The reverse transcription primer sequence (5 '-3 ') of miR-202-5p is shown in SEQ ID NO.3;
[0091] The reverse transcription primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.4.
[0092] The quality control products in Table 1 are: 5×10 4The sequence (5'-3') of cel-miRNA-39 at 100 copies / ul was shown in SEQ ID NO.13, which was UCACCGGGUGUAAAUCAGCUUG; the quality control reverse transcription primer was used for reverse transcription reaction to obtain the quality control reverse transcription sample, and the quality control reverse transcription primer sequence (5'-3') was shown in SEQ ID NO.14, which was GTCGTATCCAGTGCAGTGTCAGAGGTAGTCGCACTGGATACGACCAAGCTGA.
[0093] The reverse transcription reaction was carried out according to the conditions in Table 2, and 4°C indicated completion of the reaction.
[0094] Table 2. Reverse transcription reaction conditions for miRNA and quality control products
[0095]
[0096] (3) Using the obtained miRNA reverse transcription sample and detection primers to configure a miRNA digital PCR detection reaction system, prepare digital PCR reaction droplets, and perform a digital PCR reaction.
[0097] The miRNA digital PCR detection reaction system is shown in Table 3 (a separate tube is configured for each detection of miR-1224-5p, miR-2113, miR-202-5p, and miR-920).
[0098] Table 3. miRNA digital PCR detection reaction system
[0099]
[0100] The detection primers for the 8 miRNAs in Table 3 are:
[0101] The forward primer sequence (5'-3') of miR-1224-5p is shown in SEQ ID NO.5;
[0102] The reverse primer sequence (5 '-3 ') of miR-1224-5p is shown in SEQ ID NO.6;
[0103] The forward primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.7;
[0104] The reverse primer sequence (5'-3') of miR-2113 is shown in SEQ ID NO.8;
[0105] The forward primer sequence (5'-3') of miR-202-5p is shown in SEQ ID NO.9;
[0106] The reverse primer sequence (5'-3') of miR-202-5p is shown in SEQ ID NO.10;
[0107] The forward primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.11;
[0108] The reverse primer sequence (5'-3') of miR-920 is shown in SEQ ID NO.12.
[0109] The detection primers for the quality control products in Table 3 are:
[0110] The forward primer sequence (5'-3') is shown in SEQ ID NO. 15, which is AGGCTCACCGGGTGTAAAT;
[0111] The reverse primer sequence (5'-3') is shown in SEQ ID NO.16, which is GCAGTGCAGTGTCAGAGGTAGTC.
[0112] The configured reaction system was used to prepare digital PCR reaction droplets, which were then transferred to a 96-well plate for PCR reaction. The reaction conditions are shown in Table 4.
[0113] Table 4. Digital PCR reaction conditions
[0114]
[0115] After the reaction, transfer the 96-well plate to the QX200™ digital PCR reader to read the results.
[0116] (4) Calculation of results
[0117] 1) Calculation of quality control products: Assuming that the total RNA sample dissolution volume after extraction is A μL, and the Bio-rad QX200 digital PCR test result is B copies / μL, the concentration of the quality control product (X copies / μL) is calculated according to the following formula (1):
[0118] X copy number / μL = (B×20 / 3×15 / 3×A) / 10 = 10 / 3×A×B (1)
[0119] 2) The test results of quality control products should meet the following requirements: 4×10 4 ~5×10 4 copies / ul, if the value is met, the results of miRNA (miR-1224-5p, miR-2113, miR-202-5p, miR-920) detection of the sample are valid, otherwise the experiment is invalid and needs to be re-extracted for detection.
[0120] 3) If the quality control product results are qualified, the concentration of the target miRNA in the plasma sample (Y copies / μL) is calculated according to the following formula (2):
[0121] Y copy number / μL=(B×20 / 3×15 / 3×A) / 200=1 / 6×A×B(2)
[0122] (5) Risk assessment
[0123] First, calculate the P1 value according to the following formulas (3) and (4):
[0124] P1=e s1 / (1+e s1 )(3)
[0125] S1=4.147-0.012×m1-0.034×m2+0.013×m3+0.042×m4 (4)
[0126] Among them, m1 is the content of miR-1224-5p in the sample; m2 is the content of miR-2113 in the sample; m3 is the content of miR-202-5p in the sample; and m4 is the content of miR-920 in the sample.
[0127] When P1<0.36, it means that the subject has no liver fibrosis or only mild fibrosis (F0~1), which is early NASH; when P1>0.36, it means that the subject has significant liver fibrosis or septal fibrosis (F2~3), which is fibrotic NASH, or has cirrhosis (F4), which is NASH cirrhosis.
[0128] For patients who were classified as fibrotic NASH with significant liver fibrosis or septal fibrosis (F2-3), or NASH cirrhosis with cirrhosis (F4), the P2 value was calculated according to formulas (5) and (6):
[0129] P2=e s2 / (1+e s2 )(5)
[0130] S2=2.582+0.002×m1-0.054×m2+0.007×m3+0.026×m4 (6)
[0131] Among them, m1 is the content of miR-1224-5p in the sample; m2 is the content of miR-2113 in the sample; m3 is the content of miR-202-5p in the sample; and m4 is the content of miR-920 in the sample.
[0132] When P2<0.58, it means that the subject has no liver fibrosis or only mild fibrosis (F0~1), which is early NASH; when P2>0.58, it means that the subject has significant liver fibrosis or septal fibrosis (F2~3), which is fibrotic NASH, or has cirrhosis (F4), which is NASH cirrhosis.
[0133] Example 3
[0134] 46 patients with early NASH in stage F0-1, 41 patients with fibrotic NASH in stage F2-3, and 60 patients with NASH cirrhosis in stage F4 were included. Their plasma was collected according to the method described in Example 2, and the total miRNA in the plasma was extracted. Digital PCR reaction was performed. After the reaction, the P1 or P2 value was calculated according to the risk assessment steps, and then the data was analyzed.
[0135] GraphPad Prism software was used for analysis to obtain the ROC curve of the detection control. Figure 1 and Figure 2 , Figure 1 AUC = 0.88, sensitivity = 84.8%, specificity = 79.2% for distinguishing patients in F0-1 stage from those in F2-4 stage; Figure 2 The AUC for distinguishing patients in stages F2~3 from those in stage F4 was 0.82, with a sensitivity of 75% and a specificity of 75.6%.
[0136] The above are only preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be regarded as limiting the present invention, and the protection scope of the present invention should be based on the scope defined by the claims. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. Use of a MicroRNA marker for non-alcoholic fatty liver disease in the preparation of a reagent or a detection tool for detecting non-alcoholic fatty liver disease, characterized in that: The markers are miR-1224-5p, miR-2113, miR-202-5p and miR-920.
2. A reverse transcription primer and a detection primer for detecting a MicroRNA marker, characterized in that: The markers are markers of non-alcoholic fatty liver disease; the markers are miR-1224-5p, miR-2113, miR-202-5p and miR-920; The reverse transcription primers are: The reverse transcription primer sequence 5'-3' of miR-1224-5p is shown in SEQ ID NO.1; The reverse transcription primer sequence 5'-3' of miR-2113 is shown in SEQ ID NO.2; The reverse transcription primer sequence 5'-3' of miR-202-5p is shown in SEQ ID NO.3; The reverse transcription primer sequence 5'-3' of miR-920 is shown in SEQ ID NO.4; The detection primers are: The forward primer sequence 5'-3' of miR-1224-5p is shown in SEQ ID NO.5; The reverse primer sequence 5'-3' of miR-1224-5p is shown in SEQ ID NO.6; The forward primer sequence 5'-3' of miR-2113 is shown in SEQ ID NO.7; The reverse primer sequence 5'-3' of miR-2113 is shown in SEQ ID NO.8; The forward primer sequence 5'-3' of miR-202-5p is shown in SEQ ID NO.9; The reverse primer sequence 5'-3' of miR-202-5p is shown in SEQ ID NO.10; The forward primer sequence 5'-3' of miR-920 is shown in SEQ ID NO.11; The reverse primer sequence 5'-3' of miR-920 is shown in SEQ ID NO.
12.
3. Use of a primer for detecting the MicroRNA marker described in claim 1 in preparing a reagent or a detection tool for detecting non-alcoholic fatty hepatitis.
4. Use of the reverse transcription primer and detection primer according to claim 2 in the preparation of a reagent or a detection tool for detecting non-alcoholic fatty hepatitis.
5. A diagnostic kit for non-alcoholic fatty hepatitis, characterized in that: The kit includes reverse transcription primers and detection primers of MicroRNA markers of non-alcoholic fatty hepatitis; The microRNA markers are miR-1224-5p, miR-2113, miR-202-5p and miR-920; The reverse transcription primers are: The reverse transcription primer sequence 5'-3' of miR-1224-5p is shown in SEQ ID NO.1; The reverse transcription primer sequence 5'-3' of miR-2113 is shown in SEQ ID NO.2; The reverse transcription primer sequence 5'-3' of miR-202-5p is shown in SEQ ID NO.3; The reverse transcription primer sequence 5'-3' of miR-920 is shown in SEQ ID NO.4; The detection primers are: The forward primer sequence 5'-3' of miR-1224-5p is shown in SEQ ID NO.5; The reverse primer sequence 5'-3' of miR-1224-5p is shown in SEQ ID NO.6; The forward primer sequence 5'-3' of miR-2113 is shown in SEQ ID NO.7; The reverse primer sequence 5'-3' of miR-2113 is shown in SEQ ID NO.8; The forward primer sequence 5'-3' of miR-202-5p is shown in SEQ ID NO.9; The reverse primer sequence 5'-3' of miR-202-5p is shown in SEQ ID NO.10; The forward primer sequence 5'-3' of miR-920 is shown in SEQ ID NO.11; The reverse primer sequence 5'-3' of miR-920 is shown in SEQ ID NO.12.
